Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4.74	9.37	13.6	15.19	11.67	17.58
Short-Term Investments	11.21	10.49	26.37	45.98	0.02	0
Cash & Cash Equivalents	15.95	19.86	39.97	61.16	11.7	17.58
Cash Growth	-51.34%	-50.31%	-34.65%	422.83%	-33.44%	133.80%
Receivables	0.89	1.04	1.77	1.53	0.14	0
Other Current Assets	0	0	0	0	0	0.64
Total Current Assets	16.84	20.9	41.74	62.69	11.84	18.21
Property, Plant & Equipment	0.66	0.7	0.59	0.7	0.58	1.36
Long-Term Investments	0	0	0	0.06	0.06	0.13
Other Long-Term Assets	0.52	0.56	0.73	0.91	0	0.06
Total Long-Term Assets	1.17	1.25	1.33	1.67	0.64	1.54
Total Assets	18.01	22.15	43.06	64.35	12.48	19.76
Accounts Payable	0.53	0.52	1.69	1.34	0.09	0.88
Current Debt	0.11	0.08	0.12	0.11	0.07	0.39
Other Current Liabilities	3.76	4.25	4.94	1.21	1.15	2.86
Total Current Liabilities	4.4	4.84	6.75	2.65	1.32	4.12
Long-Term Debt	0.28	0.32	0.09	0.24	0.36	0.73
Total Long-Term Liabilities	0.28	0.32	0.09	0.24	0.36	0.73
Total Liabilities	4.68	5.15	6.84	2.89	1.67	4.85
Total Debt	0.39	0.39	0.21	0.34	0.43	1.12
Debt Growth	120.34%	83.18%	-37.61%	-19.86%	-61.65%	-
Retained Earnings	-92.55	-88.68	-63.82	-36.17	-23.7	-105.43
Comprehensive Income	0	0	0	0	0	0.87
Shareholders' Equity	13.33	17	36.22	61.47	10.8	14.91
Net Cash / Debt	15.56	19.47	39.76	60.82	11.27	16.46
Net Cash / Debt Growth	-52.27%	-51.03%	-34.63%	439.65%	-31.53%	118.96%
Net Cash Per Share	0.05	0.08	0.17	0.29	0.08	1.91
Working Capital	12.44	16.06	34.99	60.04	10.52	14.09
Book Value Per Share	0.94	1.45	3.18	5.92	1.58	34.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).